Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. The Pan-American Collaborative Retina Study Group at 24 Months

Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin; Genentech, Inc., San Francisco, CA; 1.25 or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2009

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/22731

Acceso en línea:

https://doi.org/10.1016/j.ophtha.2009.03.016
https://repository.urosario.edu.co/handle/10336/22731

Palabra clave:

Bevacizumab
Adult
Aged
Argentina
Article
Brazil
Cataract
Cerebrovascular accident
Colombia
Comparative study
Controlled study
Costa rica
Diabetic macular edema
Diabetic retinopathy
Drug dose comparison
Eye examination
Female
Fluorescence angiography
Follow up
Functional anatomy
Heart infarction
Human
Hypertension
Intervention study
Intraocular pressure
Major clinical study
Male
Mexico
Ophthalmoscopy
Optical coherence tomography
Peru
Priority journal
Retina detachment
Retina macula lutea
Retrospective study
Side effect
Spain
Thickness
United states
Venezuela
Visual acuity

Rights

License

Abierto (Texto Completo)